JP2023510604A - 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 - Google Patents

再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 Download PDF

Info

Publication number
JP2023510604A
JP2023510604A JP2022543411A JP2022543411A JP2023510604A JP 2023510604 A JP2023510604 A JP 2023510604A JP 2022543411 A JP2022543411 A JP 2022543411A JP 2022543411 A JP2022543411 A JP 2022543411A JP 2023510604 A JP2023510604 A JP 2023510604A
Authority
JP
Japan
Prior art keywords
btk inhibitor
dose
lesions
weeks
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022543411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510604A5 (https=
Inventor
ミーヒョン・チョ
ティモシー・ジェイ・ターナー
エーリク・ヴァルストレーム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2023510604A publication Critical patent/JP2023510604A/ja
Publication of JP2023510604A5 publication Critical patent/JP2023510604A5/ja
Priority to JP2025155610A priority Critical patent/JP2026001038A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022543411A 2020-01-20 2021-01-19 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 Pending JP2023510604A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025155610A JP2026001038A (ja) 2020-01-20 2025-09-19 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062963238P 2020-01-20 2020-01-20
US62/963,238 2020-01-20
US202062970502P 2020-02-05 2020-02-05
US62/970,502 2020-02-05
US202063013895P 2020-04-22 2020-04-22
US63/013,895 2020-04-22
PCT/US2021/013883 WO2021150476A1 (en) 2020-01-20 2021-01-19 Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025155610A Division JP2026001038A (ja) 2020-01-20 2025-09-19 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2023510604A true JP2023510604A (ja) 2023-03-14
JP2023510604A5 JP2023510604A5 (https=) 2024-01-26

Family

ID=74626161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022543411A Pending JP2023510604A (ja) 2020-01-20 2021-01-19 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
JP2025155610A Pending JP2026001038A (ja) 2020-01-20 2025-09-19 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025155610A Pending JP2026001038A (ja) 2020-01-20 2025-09-19 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤

Country Status (12)

Country Link
US (2) US11969418B2 (https=)
EP (1) EP4093397A1 (https=)
JP (2) JP2023510604A (https=)
KR (1) KR20220130179A (https=)
CN (1) CN115348862A (https=)
AU (1) AU2021209608A1 (https=)
BR (1) BR112022014058A2 (https=)
CA (1) CA3168146A1 (https=)
IL (1) IL294560A (https=)
MX (1) MX2022008875A (https=)
TW (1) TWI883107B (https=)
WO (1) WO2021150476A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022014058A2 (pt) 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
AU2021398051A1 (en) * 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4328226A4 (en) * 2021-04-23 2025-08-27 Hangzhou Solipharma Co Ltd CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF
CN117412749A (zh) * 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
WO2022257845A1 (zh) * 2021-06-11 2022-12-15 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
CA3260159A1 (en) * 2022-06-30 2024-01-04 Principia Biopharma Inc. Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis
EP4601647A1 (en) * 2022-10-11 2025-08-20 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for multiple sclerosis
AU2023408758A1 (en) * 2022-12-20 2025-07-31 Principia Biopharma Inc. Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
JP2026505764A (ja) 2023-02-01 2026-02-18 プリンシピア バイオファーマ インコーポレイテッド 多発性硬化症を診断及び治療する方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516935A (ja) * 2015-06-03 2018-06-28 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2465328C (en) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
CN101056877B (zh) 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
TW200911803A (en) 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CN103502249A (zh) 2011-05-17 2014-01-08 普林斯匹亚生物制药公司 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
WO2015132799A2 (en) 2014-02-03 2015-09-11 Cadila Healthcare Limited Novel heterocyclic compounds
US10253023B2 (en) 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
SI3377484T1 (sl) 2015-11-17 2024-02-29 Merck Patent Gmbh Postopki za zdravljenje multiple skleroze z uporabo pirimidinskih in piridinskih spojin z btk inhibitorno aktivnostjo
BR112022014058A2 (pt) 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4328226A4 (en) 2021-04-23 2025-08-27 Hangzhou Solipharma Co Ltd CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516935A (ja) * 2015-06-03 2018-06-28 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MONTALBAN, X. ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 380, no. 25, JPN6024050815, 10 May 2019 (2019-05-10), pages 2406 - 2417, ISSN: 0005709701 *

Also Published As

Publication number Publication date
WO2021150476A1 (en) 2021-07-29
TW202140002A (zh) 2021-11-01
EP4093397A1 (en) 2022-11-30
TWI883107B (zh) 2025-05-11
MX2022008875A (es) 2022-08-11
CA3168146A1 (en) 2021-07-29
US20240366585A1 (en) 2024-11-07
US20210244720A1 (en) 2021-08-12
CN115348862A (zh) 2022-11-15
US11969418B2 (en) 2024-04-30
KR20220130179A (ko) 2022-09-26
BR112022014058A2 (pt) 2022-09-13
IL294560A (en) 2022-09-01
AU2021209608A1 (en) 2022-09-15
JP2026001038A (ja) 2026-01-06

Similar Documents

Publication Publication Date Title
JP2023510604A (ja) 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
US20170348263A1 (en) Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US20250262193A1 (en) Therapeutic Tyrosine Kinase Inhibitors For Multiple Sclerosis and Myasthenia Gravis
CN102238868A (zh) 使用颗粒状5-氨基水杨酸治疗肠病的组合物和方法
JP2023522623A (ja) 全身性過炎症反応を伴う状態の処置に使用するエクリタセルチブ
JP2026505367A (ja) 高タンパク尿慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの合剤
US20260027100A1 (en) Therapeutic tyrosine kinase inhibitors for myelin oligodendrocyte glycoprotein antibody disease (mogad)
RU2842678C1 (ru) Терапевтические ингибиторы тирозинкиназы для лечения рецидивирующего рассеянного склероза (rms)
US20240173313A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
US20260060974A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
WO2025168614A1 (en) Pharmaceutical compositions comprising azd0780
KR20240021760A (ko) 알츠하이머병의 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250520

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919